BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin’s differentiated, non-invasive DIFS approach Publication adds to Nexalin’s growing body of peer-reviewed evidence across insomnia and depression, TBI and PTSD, Alzheimer’s disease and ADHD Houston, TX, April 09, 2026 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced another publication of a peer-reviewed study in BMC Psychiatry reporting that Nexalin’s DIFS 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with non-suicidal...

Vancouver, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce further positive oxide antimony-gold drill results at its Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada. All holes completed in the 2025 drill program are now released, with further assays pending on the 35 holes completed on the Crushed and Run of Mine (“ROM”) historical gold leach pads. The Company is focused on completing the maiden antimony-gold Mineral Resource Estimate (“MRE”) in Q2-2026. The maiden MRE is a key step in the development of Limo Butte with the objective of achieving near-term antimony production by 2027 from the historical gold leach pads, while also advancing the rest of the Project for future gold-antimony development. NevGold...

Notice to Convene the Extraordinary General Meeting in RIAS A/S on 6 May 2026Attachment2026-05-06_Notice to Convene the Extraordinary General Meeting

VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) — Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) provides an update on matters related to the Entrée/Oyu Tolgoi joint venture (the “Entrée/Oyu Tolgoi JV”) mining licenses as well as drill and regional exploration results received from the Company’s joint venture partner Oyu Tolgoi LLC (“OT LLC”). ENTRÉE/OYU TOLGOI JV LICENSES UPDATEThe Company continues to focus its efforts on the transfer of the Shivee Tolgoi and Javkhlant mining licenses (the “JV Licenses”) from the Company’s Mongolian subsidiary Entrée LLC to OT LLC. Transfer of the JV Licenses is necessary to enable Lift 1 Panel 1 underground development work on the Shivee Tolgoi mining license area to proceed. On March 25, 2026, the Company delivered a non-binding proposal to the Minister...

Exodus Pay gives users a single app to spend with merchants, send money instantly, and earn rewards, all while keeping full custody OMAHA, Neb., April 09, 2026 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus”) today announced the launch of Exodus Pay, which lets users spend, send, and manage digital assets while retaining full control of their money. Exodus Pay is available today on iOS, Android, and desktop in select states including Nebraska, Texas, Florida, New York, and California, with full national rollout through April. Exodus Pay is built for people who want their money to move faster without fees, while retaining control. Users manage USD-backed stablecoins in a self-custodial wallet, with private keys stored on their device. “We spent a decade building a wallet that millions of people trust with...

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical power to support the high end of anticipated VYD2311 efficacy Invivyd conducted a pre-specified sample size re-estimation analysis when 1,500 of 1,818 enrolled patients reached Day 45 of 90 total days (April 6th), designed to add robustness given future event rate variability; that upsizing was triggered and increases confidence in overall study statistical power DECLARATION upsizing provides ~500 additional subjects and will likely shift study result timing modestly, by approximately two months, from original “mid-year” guidance to Q3 2026 Invivyd and the U.S. FDA have aligned on an initial Pediatric Study Plan for the BLA-directed pivotal pediatric immunobridging...

VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) — Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”), is pleased to announce that it has acquired an option on mineral concessions aggregating 600 hectares (“ha”) adjacent to its Tipicancha target at its Sombrero Project in Peru. The optioned concessions (the “Horizonte Concessions”) are located in an area where the Company’s expanding Tipicancha epithermal-porphyry system is believed to continue beyond the boundaries of the current Sombrero Project. In 2025, while in discussions regarding the Horizonte Concessions, Coppernico staked an additional 1,400 ha of surrounding mineral concessions. Together, these concessions substantially enhance the land position at Tipicancha, which is a priority target given its strong indicators of...

LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA)...

MIDLAND, Texas, April 09, 2026 (GLOBE NEWSWIRE) — New Era Energy & Digital, Inc. (“New Era” or the “Company”) (NASDAQ: NUAI) today announced the pricing of its previously announced underwritten public offering of 29,850,746 shares of its common stock, par value $0.0001 per share (“Common Stock”), at a price to the public of $3.35 per share, resulting in gross proceeds to the Company of approximately $100 million, before deducting the underwriters’ discount and commissions and estimated offering fees and expenses, pursuant to an effective shelf registration statement on Form S-3 (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company intends to use the net proceeds it receives from the offering to repay all outstanding borrowings under a senior secured convertible promissory...

RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) — Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the “Investors” section of the company’s website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/3k7nbxjp Participants may access the presentation telephonically by registering with the following link: https://register-conf.media-server.com/register/BIea9b995134de41e68f49a057c2a6cb66 (Registrants...